立体定向放疗后对手术腔进行定期磁共振随访在一至三个脑转移瘤患者中的影响
回顾性分析75例一至三个脑转移瘤手术切除后接受立体定向放疗(SRS或HFSRT)至手术腔的患者,评估定期磁共振随访对总生存、无症状生存、全脑放疗推迟等的影响。结果显示定期MRI随访与OS、SFS、WFS及WBRT推迟均无显著相关,作者认为其影响需前瞻性评估。
要点
- 定期MRI随访(放疗后3个月或每180天≥1次)与OS、SFS、WFS及WBRT推迟均无显著相关。
- 1年局部控制率72%、远处脑控制率60%、总生存率66%。
- 计划靶体积>15 cm3、GPA评分及术后残留肿瘤与总生存降低相关。
核心结论
- 定期MRI随访未增加总生存、无症状生存、无全脑放疗生存或全脑放疗推迟,作者认为其影响需前瞻性评估。
研究设计与样本
- 回顾性分析75例一至三个脑转移瘤患者,术后接受立体定向放射外科(SRS)或低分次立体定向放疗(HFSRT)至手术腔,未切除的脑转移灶单独用SRS处理。
主要发现
- 63例(84%)有1个脑转移瘤,11例(15%)有2个,1例(1%)有3个。
- 40例(53%)在放疗后3个月接受MRI随访,38例(51%)每180天接受≥1次脑MRI。
- 中位总生存19.4个月(95%CI:13.2-25.6个月),1年局部控制率72%(95%CI:60-83%)、远处脑控制率60%(95%CI:48-72%)、总生存率66%(95%CI:53-76%)。
- 多因素分析中,计划靶体积>15 cm3(p=0.01)、GPA评分(p=0.001)及术后残留肿瘤(p=0.008)为总生存降低的预后因素。
- 放疗后3个月MRI随访与OS(p=0.462)、SFS(p=0.536)、WFS(p=0.407)及WBRT推迟(p=0.955)无显著相关;每180天≥1次MRI与OS(p=0.954)、SFS(p=0.196)、WFS(p=0.308)及WBRT推迟(p=0.268)也无显著影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者结论指出定期MRI随访的影响需前瞻性评估。
- 研究为回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Administering stereotactic radiotherapy to the surgical cavity and thus omitting postoperative whole brain radiotherapy (WBRT) is a favored strategy in limited metastatic brain disease. Little is known about the impact of regular magnetic resonance imaging follow-up (MRI FU) in such patient cohorts. The aim of this study is to examine the impact of regular MRI FU and to report the oncological outcomes of patients with one to three brain metastases (BMs) treated with stereotactic radiosurgery (SRS) or hypo-fractionated stereotactic radiotherapy (HFSRT) to the surgical cavity. METHODS: We retrospectively analyzed patients who received SRS or HFSRT to the surgical cavity after resection of one to two BMs. Additional, non-resected BMs were managed with SRS alone. Survival was estimated by the Kaplan-Meier method. Prognostic factors were examined with the log-rank test and Cox proportional hazards model. Regular MRI FU was defined as performing a brain MRI 3 months after radiotherapy (RT) and/or performing ≥1 brain MRI per 180 days. Primary endpoint was local control (LC). Secondary endpoints were distant brain control (DBC), overall survival (OS) and the correlation between regular MRI FU and overall survival (OS), symptom-free survival (SFS), deferment of WBRT and WBRT-free survival (WFS). RESULTS: Overall, 75 patients were enrolled. One, 2 and 3 BMs were seen in 63 (84%), 11 (15%) and 1 (1%) patients, respectively. Forty (53%) patients underwent MRI FU 3 months after RT and 38 (51%) patients received ≥1 brain MRI per 180 days. Median OS was 19.4 months (95% CI: 13.2-25.6 months). Actuarial LC, DBC and OS at 1 year were 72% (95% CI: 60-83%), 60% (95% CI: 48-72%) and 66% (95% CI: 53-76%), respectively. A planning target volume > 15 cm3 (p = 0.01), Graded Prognostic Assessment (GPA) score (p = 0.001) and residual tumor after surgery (p = 0.008) were prognostic for decreased OS in multivariate analysis. No significant correlation between MRI FU at 3 months and OS (p = 0.462), SFS (p = 0.536), WFS (p = 0.407) or deferment of WBRT (p = 0.955) was seen. Likewise, performing ≥1 MRI per 180 days had no significant impact on OS (p = 0.954), SFS (p = 0.196), WFS (p = 0.308) or deferment of WBRT (p = 0.268). CONCLUSION: Our results regarding oncological outcomes consist with the current data from the literature. Surprisingly, regular MRI FU did not result in increased OS, SFS, WFS or deferment of WBRT in our cohort consisting mainly of patients with a single and resected BM. Therefore, the impact of regular MRI FU needs prospective evaluation. TRIAL REGISTRATION: Project ID: 2017-00033, retrospectively registered.
引用
- Bachmann N, Leiser D, Ermis E, et al. Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases. Radiat Oncol. 2019. PMID: 30871597. doi:10.1186/s13014-019-1252-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。